Article and Video CATEGORIES

Cancer Journey

Search By

 Dr. Zofia Piotrowska is with the Thoracic Oncology Program at Massachusetts General Hospital Cancer Center in Boston, Massachusetts.  More information on Dr. Piotrowska is available here: https://www.massgeneral.org/doctors/doctor.aspx?id=19711

2020 TTF EGFR Breakout PIOTROWSKA Part 1 - Current Options Upon Acquired Resistance to Osimertinib
2020 TTF EGFR Breakout, Dr. Zofia Piotrowska, Part 1 - Current and Emerging Options Upon Acquired Resistance to Osimertinib (Tagrisso)
Author
Zofia (Zosia) Piotrowska, MD, GRACE Faculty
Image
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

In this video from the EGFR Breakout Session, Dr. Zofia Piotrowska discusses current and emerging treatment options after acquired resistance to osimertinib (Tagrisso).

 

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

To join the conversation, visit https://cancergrace.org/forum.

Access to the full agenda can be found here: https://bit.ly/39131em

Full bios for attending faculty can be found here: https://bit.ly/2M0FVLH

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora